Publications
Comparative and Relative Effectiveness: A Challenge For Health Systems, Regulators, or Pharmaceutical Companies?
12 January 2014
This OHE Occasional Paper by Adrian Towse discusses Professor Bengt Jönsson’s observations in a 2011 publication about the role of relative effectiveness research (RE) in the…
Biosimilar Competition: Lessons from Europe and Prospects for the US
1 October 2014
Based on an OHE lunchtime seminar by Professor Henry Grabowski, this seminar briefing explores the lessons learned from Europe’s experience with biosimilars, and provides an analysis…
Obstructive Sleep Apnoea: Health Economics Report
1 September 2014
Obstructive sleep apnoea (OSA) is the temporary cessation of breathing during sleep because of a narrowing or closure of the pharyngeal airway. Untreated OSA can result…
What Determines the Shape of an EQ-5D Index Distribution?
1 August 2014
The EQ-5D is one of the most used health-related quality of life instruments worldwide. Understanding the characteristics of its underlying data is essential. In this paper,…
Exploring the Interdependencies of Research Funders in the UK
1 July 2014
As earlier OHE research has demonstrated, sources of funding for medical research—public, charity and private sector—are complementary, not duplicative. The three sectors also differ in their…
Opportunity Costs of Implementing NICE Decisions in NHS Wales
1 June 2014
This new research from the OHE examines how Local Health Boards (LHBs) in Wales adjust spending to meet the statutory requirement of providing access to technologies…
The Trajectory of Dementia in the UK – Making a Difference
1 June 2014
Alzheimer’s Research UK commissioned OHE Consulting to model the incidence and cost of dementia in the UK and the potential impact of better treatment. The analyses…
The Expanding Value Footprint of Oncology Treatments
1 May 2014
This report examines the importance and history of HTA evaluations for additional uses for cancer drugs after their initial approval. Included are the ten cancer drugs approved by the EMA during 2003–2005. Decisions by France’s HAS, NICE and Aetna in the US are analysed.
What is the Role of HTA for Biosimilars?
1 April 2014
This Briefing summarises the results of a roundtable convened by OHE to discuss using HTA to assess biosimilars – including which methods are most appropriate in…